Thromboprophylaxis with Low Molecular Weight Heparin after Major Orthopaedic Surgery is Cost Effective
- 1 January 1996
- journal article
- research article
- Published by Springer Nature in Drugs
- Vol. 52 (Supplement) , 42-46
- https://doi.org/10.2165/00003495-199600527-00008
Abstract
The objective of this analysis was to evaluate the socioeconomic consequences of routine administration of low molecular weight heparin (LMWH) as thromboprophylaxis in patients undergoing total hip arthroplasty, on the basis of data from a number of clinical studies. Despite the higher direct costs associated with LMWH, this regimen was more cost effective per thromboembolic complication prevented than no prophylaxis, dextran 70, or low dose un-fractionated heparin. A sensitivity analysis was performed to address the outcome when the main factors in the economic analysis were changed; this had no significant effect on the conclusions of the study.Keywords
This publication has 7 references indexed in Scilit:
- Perioperative thrombosis prophylaxis with low molecular weight heparins in elective hip surgery. Clinical and economic considerations.1994
- Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement.1994
- Prevention of Deep-Vein Thrombosis following Total Hip Replacement Surgery with Enoxaparin versus Unfractionated Heparin: A Pharmacoeconomic EvaluationAnnals of Pharmacotherapy, 1994
- Incidence of Posthospitalization Proximal Deep Venous Thrombosis After Total Hip Arthroplasty A Pilot StudyClinical Orthopaedics and Related Research, 1994
- Low-molecular-weight heparin (enoxaparin) vs dextran 70. The prevention of postoperative deep vein thrombosis after total hip replacement. The Danish Enoxaparin Study GroupArchives of internal medicine (1960), 1991
- Deep venous thrombosis: a continuing problem.BMJ, 1988
- The economics of general thromboembolic prophylaxisWorld Journal of Surgery, 1988